Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announces they have entered a non-binding Memorandum of Understanding (MOU) to acquire Marizyme (OTC: MRZM).Marizyme’s DuraGraft is an FDA cleared platform technology in the Coronary Artery Bypass Graft (CABG) market. The CABG market is over $10 billion in revenue annually. It is estimated there are more than 500,000 CABG surgeries performed every year in the US.
Read the full article: Qualigen Seeks to Enter the $10B CABG Market with Non-Binding MOU to Acquire Marizyme //
Source: https://www.globenewswire.com/news-release/2025/04/01/3053296/0/en/Qualigen-seeks-to-enter-the-10-Billion-CABG-market-with-non-binding-MOU-to-acquire-Marizyme.html